157 related articles for article (PubMed ID: 21752527)
1. Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?
Skałba P; Cygal A; Madej P; Dąbkowska-Huć A; Sikora J; Martirosian G; Romanik M; Olszanecka-Glinianowicz M
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):254-9. PubMed ID: 21752527
[TBL] [Abstract][Full Text] [Related]
2. Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin-Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results.
Yetim A; Yetim Ç; Baş F; Erol OB; Çığ G; Uçar A; Darendeliler F
J Clin Res Pediatr Endocrinol; 2016 Sep; 8(3):288-97. PubMed ID: 27125339
[TBL] [Abstract][Full Text] [Related]
3. The correlation between serum AMH and HOMA-IR among PCOS phenotypes.
Wiweko B; Indra I; Susanto C; Natadisastra M; Hestiantoro A
BMC Res Notes; 2018 Feb; 11(1):114. PubMed ID: 29426356
[TBL] [Abstract][Full Text] [Related]
4. AMH as part of the diagnostic PCOS workup in large epidemiological studies.
Piltonen TT; Komsi E; Morin-Papunen LC; Korhonen E; Franks S; Järvelin MR; Arffman RK; Ollila MM
Eur J Endocrinol; 2023 Jun; 188(6):547-554. PubMed ID: 37294941
[TBL] [Abstract][Full Text] [Related]
5. The relationship between Anti-Müllerian hormone and other reproductive parameters in normal women and in women with polycystic ovary syndrome.
Koutlaki N; Dimitraki M; Zervoudis S; Poiana C; Psillaki A; Nikas I; Liberis A; Badiu C; Liberis V
J Med Life; 2013 Jun; 6(2):146-50. PubMed ID: 23904873
[TBL] [Abstract][Full Text] [Related]
6. Association of anti-Müllerian hormone and insulin resistance in adolescent girls with polycystic ovary syndrome.
Guo G; Zheng H; Wu X
Endokrynol Pol; 2024; 75(1):83-88. PubMed ID: 38497393
[TBL] [Abstract][Full Text] [Related]
7. Obesity contributes to telomere shortening in polycystic ovary syndrome.
Kogure GS; Verruma CG; Santana BA; Calado RT; Ferriani RA; Furtado CLM; Dos Reis RM
Reprod Sci; 2024 Jun; 31(6):1601-1609. PubMed ID: 38393627
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of vit D and AMH and its correlation with polycystic ovarian parameters in obese and non-obese Egyptian women.
Hegazy M; El-Mahdy HA; Elsayed TS; Elkhawaga SY; Elkady MA; Yehia AM; El-Husseiny AA; Shaban HM; Gomaa MH; Mokhtar MM
Pathol Res Pract; 2023 Nov; 251():154872. PubMed ID: 37820441
[TBL] [Abstract][Full Text] [Related]
9. Metabolic disparities between obese and non-obese patients with polycystic ovary syndrome: implications for endometrial receptivity indicators.
Li XL; Ji YF; Feng Y; Liu SW
Gynecol Endocrinol; 2024 Dec; 40(1):2312895. PubMed ID: 38444321
[TBL] [Abstract][Full Text] [Related]
10. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome.
Ebrahimi-Mamaghani M; Saghafi-Asl M; Pirouzpanah S; Aliasgharzadeh A; Aliashrafi S; Rezayi N; Mehrzad-Sadaghiani M
J Health Popul Nutr; 2015 Mar; 33(1):157-67. PubMed ID: 25995732
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
12. Serum LH levels are associated to serum insulin and Anti-Müllerian hormone levels in women with both functional hypothalamic amenorrhoea and polycystic ovarian morphology.
Makolle S; Catteau-Jonard S; Robin G; Dewailly D
Clin Endocrinol (Oxf); 2023 Jul; 99(1):73-78. PubMed ID: 36912207
[TBL] [Abstract][Full Text] [Related]
13. The effects of dietary approaches to stop hypertension diet on weight loss, anti-Müllerian hormone and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial.
Foroozanfard F; Rafiei H; Samimi M; Gilasi HR; Gorjizadeh R; Heidar Z; Asemi Z
Clin Endocrinol (Oxf); 2017 Jul; 87(1):51-58. PubMed ID: 28316072
[TBL] [Abstract][Full Text] [Related]
14. Body mass index is a good predictor of metabolic abnormalities in polycystic ovary syndrome.
Fruzzetti F; Fidecicchi T; Benelli E; Baldari F; Tonacchera M
J Endocrinol Invest; 2024 Apr; 47(4):927-936. PubMed ID: 37907709
[TBL] [Abstract][Full Text] [Related]
15. The association of thyroid autoimmunity with ovarian reserve in women with type 1 diabetes with and without polycystic ovary syndrome.
Łebkowska A; Krentowska A; Adamska A; Uruska A; Rogowicz-Frontczak A; Araszkiewicz A; Ożegowska K; Leśniewska M; Sowa P; Wender-Ożegowska E; Zozulińska-Ziółkiewicz D; Kowalska I
Sci Rep; 2024 Jun; 14(1):13223. PubMed ID: 38851814
[TBL] [Abstract][Full Text] [Related]
16. Increased body mass index is negatively associated with ovarian reserve as measured by anti-Müllerian hormone in patients with polycystic ovarian syndrome.
Kloos J; Perez J; Weinerman R
Clin Obes; 2024 Jun; 14(3):e12638. PubMed ID: 38156530
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for insulin resistance related to polycystic ovarian syndrome in Iranian population.
Mansour A; Mirahmad M; Mohajeri-Tehrani MR; Jamalizadeh M; Hosseinimousa S; Rashidi F; Asili P; Sajjadi-Jazi SM
Sci Rep; 2023 Jun; 13(1):10269. PubMed ID: 37355686
[TBL] [Abstract][Full Text] [Related]
18. Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial.
Zhao H; Zhang J; Xing C; Cheng X; He B
J Ovarian Res; 2024 Feb; 17(1):42. PubMed ID: 38374053
[TBL] [Abstract][Full Text] [Related]
19. Assessing the clinical diagnostic value of anti-Müllerian hormone in polycystic ovarian syndrome and its correlation with clinical and metabolism indicators.
Wang L; Luo M; Yu X; Li R; Ye F; Xiong D; Gong Y; Zheng M; Liu W; Zeng J
J Ovarian Res; 2024 Apr; 17(1):78. PubMed ID: 38600539
[TBL] [Abstract][Full Text] [Related]
20. Cardio-metabolic risk in Rotterdam clinical phenotypes of PCOS.
Mitra S; Saharia GK; Jena SK
Ann Endocrinol (Paris); 2024 Feb; 85(1):44-47. PubMed ID: 37328054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
